GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Sagimet Biosciences (Sagimet Biosciences) Cash, Cash Equivalents, Marketable Securities : $193.71 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities?

Sagimet Biosciences's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($101.84 Mil) to Dec. 2023 ($94.90 Mil) but then increased from Dec. 2023 ($94.90 Mil) to Mar. 2024 ($193.71 Mil).

Sagimet Biosciences's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($56.73 Mil) to Dec. 2022 ($32.35 Mil) but then increased from Dec. 2022 ($32.35 Mil) to Dec. 2023 ($94.90 Mil).


Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sagimet Biosciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
10.21 68.70 56.73 32.35 94.90

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.25 18.51 101.84 94.90 193.71

Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Sagimet Biosciences  (NAS:SGMT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagimet Biosciences (Sagimet Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Executives
David Happel director, officer: President & CEO 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Beth C Seidenberg director
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth Rozek officer: General Counsel and CCO SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402
George Kemble director SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402
Jinzi Jason Wu director SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402
Dennis Hom officer: Chief Financial Officer C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Kpcb Pbd Associates, Llc 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Kpcb Pandemic & Bio Defense Fund Llc 10 percent owner 2750 SAND HILL RD, MENLO PARK CA 94025
Eduardo Bruno Martins director 350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer director 78TH FOURTH AVENUE, WALTHAM MA 02451
Anthony M Rimac officer: Chief Operating Officer C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608
Patrick J Kerins 10 percent owner